Baseline characteristics of the nocturnal haemodialysis (NHD) and haemodialysis/haemodiafiltration (HD/HDF) cohorts after propensity-score matching
| NHD (n=100)* | HD/HDF (n=100)* | Standardised mean difference | |
| Demographics | |||
| Age (years) | 56.7±12.9 | 56.3±15.1 | 0.03 |
| Male (%) | 68 | 67 | 0.02 |
| BMI (kg/m2) | 25.9±5.6 | 25.9±5.1 | 0.01 |
| Medical history | |||
| Dialysis vintage (years) | 2.3 (0.9–5.1) | 2.1 (1.1–4.0) | <0.01 |
| Cause of ESRD (%) | |||
| Glomerulonephritis | 24 | 16 | 0.54 |
| Interstitial nephritis | 13 | 6 | |
| Cystic kidney disease | 16 | 9 | |
| Congenital, other | 4 | 1 | |
| Renovascular | 19 | 27 | |
| Diabetes mellitus | 9 | 16 | |
| Multisystem disease | 5 | 6 | |
| Other | 6 | 10 | |
| Unknown | 5 | 9 | |
| Current smoker (%) | 19 | 19 | 0.02 |
| Comorbidities (%) | |||
| Diabetes mellitus | 21 | 19 | 0.02 |
| Cardiovascular disease | 30 | 29 | 0.02 |
| Transplant waiting-list listed (%) | 28 | 28 | <0.001 |
| Phosphate control | |||
| Phosphate (mmol/L) | 1.72±0.52 | 1.69±0.53 | 0.05 |
| Different phosphate binding agents | 1.40±0.74 | 1.43±0.64 | 0.05 |
| Vitamin D usage (%) | 84 | 67 | 0.40 |
| Hypertension control | |||
| Systolic blood pressure (mm Hg) | 143.0±21.7 | 143.7±21.1 | 0.03 |
| Diastolic blood pressure (mm Hg) | 79.4±13.2 | 79.7±12.7 | 0.02 |
| Different antihypertensive agents | 1.22±1.18 | 1.15±0.95 | 0.07 |
| Nutritional status/inflammation | |||
| Postdialysis weight (kg) | 77.5±16.8 | 75.5±15.4 | 0.13 |
| Creatinine (µmol/L) | 863±260 | 938±273 | 0.28 |
| Albumin (g/L) | 40.6±3.0 | 40.6±3.8 | 0.02 |
| CRP (mg/L) | 5.0 (2.3–13.6) | 3.7 (1.4–10.1) | 0.02 |
| Cholesterol (mmol/L) | 3.9±1.0 | 3.9±1.0 | <0.01 |
| Anaemia control | |||
| Hb (mmol/L) | 7.1±0.8 | 7.4±0.7 | 0.35 |
| ESA dose (DDD) | 8.0 (4.4–13.3) | 6.7 (4.0–13.3) | 0.04 |
| ESA resistance index (DDD/Hb/kg/week) | 0.01 (0.01–0.03) | 0.01 (0.01–0.03) | 0.01 |
| Use of iron supplementation (%) | 87 | 86 | 0.01 |
| Dialysis treatment parameters and residual kidney function | |||
| Residual diuresis >100 mL/24 hours (%) | 49 | 50 | 0.04 |
| Residual GFR (mL/min)† | 0.0 (0.0–3.7) | 0.0 (0.0–2.7) | 0.08 |
| Central venous catheter (%) | 4 | 5 | 0.04 |
| Weekly dialysis sessions | 3.0±0.7 | 3.0±0.1 | 0.02 |
| Weekly dialysis hours | 11.7±2.2 | 11.6±1.1 | 0.05 |
*M edian 200 (IQR 198 – 202) matched cases.
†Mean of urea/creatinine clearance, 0 when residual diuresis <100 mL/24 hours. We report data as mean±SD, median (IQR) or proportions where appropriate. Standardised mean differences<0.1 are considered balanced.
BMI, body mass index; CRP, C reactive protein; DDD, defined daily dose; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; GFR, glomerular filtration rate; Hb, haemoglobin; HD, haemodialysis; HDF, haemodiafiltration; NHD, nocturnal HD.